MICOT PHARMA-B

Micot-B opened sharply lower during the morning session and continued to weaken, closing at HK$28.72, down 5.84%, with an intraday low of HK$28.72 near its 52-week trough, representing a 36.23% retreat from the 52-week high of HK$45.04. The sell-off was primarily driven by persistent weakness across the Hong Kong biotech sector, with the stock having experienced multiple single-day declines exceeding 10% in the past week amid heightened capital activity. The negative price action overshadowed the company's recent announcement of database lock completion for its Phase II trial of MT200605 in acute ischemic stroke. The stock has fallen below both its 20-day moving average of HK$33.90 and 60-day moving average of HK$35.89, with a year-to-date decline of 22.17%, though it still trades at a 6.37% premium to its 52-week low of HK$27.00. However, the company remains pre-revenue with a negative P/E ratio of -47.15x, as market valuation for unprofitable innovative drug developers continues to face divergence.

Micot Pharma-B (2335.HK) fell 5.1% to close at HK$29.30, with losses deepening in the afternoon session, primarily due to persistent weakness in the biotech sector and profit-taking after recent volatility. The stock hit an intraday high of HK$31.18 before retreating, reaching a low of HK$29.30 in the afternoon, with turnover of HK$8.82 million, up from the previous day. On the news front, the company announced the database lock for its Phase II trial of MT200605 for ischemic stroke and the enrollment of the first patient in the Phase II trial of MT1002 for anticoagulation in hemodialysis patients, but these milestones failed to support the stock. The current price is 34.95% below the 52-week high of HK$45.04 and trades below both the 20-day (HK$34.558) and 60-day (HK$36.079) moving averages, with a YTD decline of 20.6%, indicating technical pressure. However, the company's market cap stands at approximately HK$9.72 billion, with a PB of -9.03 and PE of -48.1, reflecting ongoing losses, though the year-to-date drop has already been significant.

Macopharm-B staged a sharp reversal in the morning session, opening low and then surging 5.0% from a low of HK$28.22 to HK$29.62 within the first 24 minutes, recovering all of yesterday's 5% decline. The bounce was primarily driven by news that the company's core stroke drug candidate MT200605 completed a Phase II trial database lock, which was released during today's trading session and reversed a prolonged slump tied to biotech sector weakness. Despite the rebound, the stock remains 34.2% below the 52-week high of HK$45.04 and trades below both the 20-day MA (HK$36.74) and 60-day MA (HK$37.01), placing it in a deeply depressed price range; however, it is still down 19.7% year-to-date, with the broader downtrend yet to be broken.

Micot Pharma-B (2335.HK) opened 5.1% lower in the morning session and continued to weaken, last trading at HK$30.00 as of 09:48 BJ, down 5.06%, with the intraday low of HK$30.00 matching the 52-week low and representing a 33.39% retreat from the 52-week high of HK$45.04. Among the recent 30 news items, the stock has been under persistent pressure, with multiple single-day declines of 5%-15% in recent sessions. Today's decline is primarily attributed to broad biotech sector weakness—the completion of the Phase II trial database lock for its core stroke drug candidate MT200605 failed to lift sentiment, and the progress of the MT1002 anticoagulant Phase II enrollment also drew no positive reaction. The current price stands approximately 21% below the MA20 (HK$38.032) and MA60 (HK$38.128), with a YTD decline of 18.7%. The market cap is about HK$9.95 billion, and the turnover rate is a mere 0.01%, indicating thin trading. However, the company is advancing its Phase II pipeline, and positive data readouts could drive a re-rating.

Micot Pharma-B fell sharply on heavy volume, closing at HKD 31.600, down 7.06% on the day, with an intraday range of 12.6% after opening at HKD 34.020 and surging to HKD 34.300 before reversing to a single-session downtrend; the afternoon session extended losses to a new intraday low of HKD 30.020, near the 52-week low. The sell-off was driven by persistent negative sector sentiment without company-specific catalysts, as the stock had rallied to record highs on Phase II enrollment news of MT1002 but has since seen a series of >10% daily declines, suggesting aggressive profit-taking. At HKD 31.600, the stock sits 29.8% below its 52-week high of HKD 45.040 and has fallen below both the 20-day MA (HKD 38.459) and 60-day MA (HKD 38.481), with a YTD decline of 14.4%. However, the company announced that the Phase II database lock for its stroke candidate MT200605 has been completed, which could serve as a potential catalyst upon future data readouts.